DISCOVERIES REPORTS (ISSN 2393249X), 2023, volume 6
ORIGINAL ARTICLE
CITATION: Chera A. A new FDA approved drug combination for adults with asthma: albuterol and budesonide. Discoveries Reports 2023; 6: e38. DOI: 10.15190/drep.2023.2
A new FDA approved drug combination for adults with asthma: albuterol and budesonide
Alexandra Chera 1,2, *
1 Nicolae Malaxa Clinical Hospital, Bucharest, Romania
2 Victor Babes National Institute of Pathology, Bucharest, Romania
* Corresponding authors:
Alexandra Chera, MD, Allergy and Clinical Immunology Medical Resident, Nicolae Malaxa Clinical Hospital, Bucharest, Romania; Next Generation Pathology Group (nextgenpathology.eu), Victor Babes National Institute of Pathology, 99-101 Splaiul Independentei, Sector 5, Bucharest, Romania, Email: alexandrachera19@gmail.com
Abstract
With a prevalence at around 5.1-8.2%, asthma is considered an important public health problem which decreases the quality of life of an ever-increasing number of patients, as its incidence is on the rise every year. After the recent Global Initiative for Asthma (GINA) guidelines modifications in 2019, there is a growing need of changing the perspective and habits of patients who have lived with asthma for many years, as it has been discovered that using short-acting beta-2 agonists (SABAs) as relievers without simultaneously using inhaled corticosteroids (ICS) is dangerous and could lead to increased mortality if SABAs are overused. In January 2023, FDA has approved the first drug combination of an ICS with a SABA marketed as a reliever therapy, Airsupra (PT027; 90 μg albuterol/80 μg budesonide), which has shown promising results in mild-to-moderate and moderate-to-severe cases of asthma in adult patients (≥18 years-old). Using this fixed-dose combination might decrease the risk of asthma exacerbation through its anti-inflammatory properties, while also relieving acute symptoms of bronchoconstriction and simplifying the patients’ therapeutic scheme.
Access FULL text of the manuscript here: FULL ARTICLE (PDF)
REFERENCES
1. Wecker H, Tizek L, Ziehfreund S, et al. Impact of asthma in Europe: A comparison of web search data in 21 European countries. World Allergy Organ J. 2023;16(8):100805. doi:10.1016/j.waojou.2023.100805
2. World Health Organization (WHO). Noncommunicable diseases. Accessed December 26, 2023. https://www.who.int/health-topics/noncommunicable-diseases
3. Centers for Disease Control and Prevention (CDC). Most Recent National Asthma Data | CDC. Published June 23, 2023. Accessed December 26, 2023. https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm
4. Medication for people with asthma. In: InformedHealth.Org [Internet]. Institute for Quality and Efficiency in Health Care (IQWiG); 2017. Accessed December 26, 2023. https://www.ncbi.nlm.nih.gov/books/NBK279519/
5. Canonica GW. Treating asthma as an inflammatory disease. Chest. 2006;130(1 Suppl):21S-28S. doi:10.1378/chest.130.1_suppl.21S
6. Liang TZ, Chao JH. Inhaled Corticosteroids. In: StatPearls. StatPearls Publishing; 2023. Accessed December 26, 2023. http://www.ncbi.nlm.nih.gov/books/NBK470556/
7. Sharma S, Hashmi MF, Chakraborty RK. Asthma Medications. In: StatPearls. StatPearls Publishing; 2023. Accessed December 26, 2023. http://www.ncbi.nlm.nih.gov/books/NBK531455/
8. Mauer Y, Taliercio RM. Managing adult asthma: The 2019 GINA guidelines. Cleve Clin J Med. 2020;87(9):569-575. doi:10.3949/ccjm.87a.19136
9. Mindo. GINA 2019: A paradigm shift. Medical Independent. Published June 5, 2019. Accessed December 26, 2023. https://www.medicalindependent.ie/societies/its/gina-2019-a-paradigm-shift/
10. AstraZeneca. Airsupra (PT027) approved in the US for asthma. Published January 11, 2023. Accessed December 26, 2023. https://www.astrazeneca.com/media-centre/press-releases/2023/airsupra-pt027-approved-in-the-us-for-asthma.html
11. 2019 GINA Report: Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma - GINA. Published 2019. Accessed December 26, 2023. https://ginasthma.org/reports/2019-gina-report-global-strategy-for-asthma-management-and-prevention/
12. AstraZeneca. Drug Label: AIRSUPRATM (albuterol 90 mcg/budesonide 80 mcg) Inhalation Aerosol. Published 2023. Accessed December 26, 2023. https://www.airsupra.com
13. United States Food & Drug Administration. FDA approves drug combination treatment for adults with asthma. FDA. Published online January 11, 2023. Accessed December 26, 2023. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-combination-treatment-adults-asthma
14. Bond Avillion 2 Development LP. A Long-Term, Randomized, Double-Blind, Multicenter, Parallel-Group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in Symptomatic Adults and Children 4 Years of Age or Older With Asthma. clinicaltrials.gov; 2022. Accessed January 1, 2023. https://clinicaltrials.gov/study/NCT03769090
15. Bond Avillion 2 Development LP. A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT008 and PT007 Administered QID in Adults and Children 4 Years of Age or Older With Asthma. clinicaltrials.gov; 2023. Accessed January 1, 2023. https://clinicaltrials.gov/study/NCT03847896
16. Chipps BE, Israel E, Beasley R, et al. Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma: Results of the DENALI Double-Blind Randomized Controlled Trial. Chest. 2023;164(3):585-595. doi:10.1016/j.chest.2023.03.035
